LUNG CANCER SURGERY MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The global Lung Cancer Surgery market size was valued at US$ 6.40 billion in 2023 and is expected to reach US$ 9.50 billion by 2030, grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030

The lung cancer surgery market has witnessed significant growth and innovation in recent years, driven by advancements in medical technology, increasing awareness about early detection, and improving healthcare infrastructure. Surgical interventions play a crucial role in the management of lung cancer, particularly for patients with localized tumors or those for whom surgery presents a viable option. Procedures like lobectomy, pneumonectomy, and minimally invasive techniques such as video-assisted thoracic surgery (VATS) have gained prominence, offering patients reduced postoperative complications and faster recovery times. This growing demand for effective surgical treatments has spurred investments in research and development, leading to the introduction of novel surgical instruments, robotics, and imaging technologies tailored to enhance the precision and outcomes of lung cancer surgeries.

Geographically, the lung cancer surgery market exhibits variations based on factors such as regional healthcare expenditure, prevalence of lung cancer, and access to advanced medical facilities. Developed economies with robust healthcare systems have witnessed a higher adoption of advanced surgical techniques, contributing to a larger market share. Meanwhile, emerging economies are also witnessing an increased focus on improving lung cancer diagnosis and treatment infrastructure, which is expected to drive market growth in those regions.

Lung Cancer Surgery Market Regional Insights

• North America: North America is the largest market for Lung Cancer Surgery, accounting for a share of over 38.4% in 2022. North America, particularly the United States and Canada, has well-established healthcare systems and access to advanced surgical techniques. There has been a strong emphasis on minimally invasive surgeries, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgeries, which lead to faster recovery times and reduced post-operative complications. Research and development efforts in this region have also focused on improving patient outcomes through personalized treatment approaches.
• Europe: Europe is the second-largest market for Lung Cancer Surgery, accounting for a share of over 27.2% in 2022. European countries have been adopting innovative surgical techniques for lung cancer treatment. The emphasis on multidisciplinary care, including surgery, chemotherapy, and radiotherapy, has been prominent. The availability of specialized cancer centers and a well-connected healthcare network has contributed to the adoption of advanced surgical procedures.
• Asia-Pacific: Asia Pacific is the fastest-growing market for Lung Cancer Surgery, accounting for a share of over 22.2% in 2022. The Asia-Pacific region has seen a rise in lung cancer cases due to factors like increased smoking rates, urbanization, and environmental pollution. Countries like China, Japan, and South Korea have been investing in healthcare infrastructure and technology, leading to the growth of lung cancer surgeries. There's a growing trend towards minimally invasive procedures in this region as well.

Figure 1. Global Lung Cancer Surgery Market Share (%), by Region, 2023

Lung Cancer Surgery Market Drivers:

• Increasing Prevalence of Lung Cancer: The rising incidence of lung cancer globally has been a major driver of the lung cancer surgery market. As the number of diagnosed cases increases, the demand for surgical interventions, including minimally invasive procedures and traditional open surgeries, also rises.
• Advancements in Surgical Techniques: The continuous development of surgical techniques, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery, has led to improved patient outcomes. These techniques result in smaller incisions, reduced pain, shorter hospital stays, and quicker recovery times, which are appealing to both patients and healthcare providers.
• Growing Emphasis on Early Detection: Early detection of lung cancer has become a priority in improving patient survival rates. Surgical intervention, often combined with other treatment modalities like chemotherapy and radiation therapy, is a critical component of curative intent for early-stage lung cancer.
• Personalized Treatment Approaches: Advances in molecular profiling and genomic testing have enabled the identification of specific genetic mutations and biomarkers in lung cancer tumors. This has paved the way for targeted therapies and precision medicine, influencing the choice of surgical interventions tailored to individual patient profiles.

Lung Cancer Surgery Market Opportunities:

• Adoption of Minimally Invasive Techniques: The adoption of minimally invasive surgical techniques, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery, provides significant opportunities for growth. These approaches offer quicker recovery times, reduced post-operative pain, and shorter hospital stays, making them attractive options for patients and healthcare providers.
• Precision Medicine and Targeted Therapies: Advances in molecular profiling and genetic testing create opportunities for personalized treatment approaches. Identifying specific genetic mutations and biomarkers in lung cancer tumors allows for targeted therapies, which could impact the choice of surgical interventions and lead to better patient outcomes.
• Integration of Imaging Technologies: Continued advancements in imaging technologies like high-resolution computed tomography (CT) scans and positron emission tomography (PET) scans offer opportunities for improved pre-operative planning, precise tumor localization, and accurate staging of lung cancer. These technologies enhance the success of surgical interventions.
• Telemedicine and Remote Consultations: The growth of telemedicine and remote consultations creates opportunities for accessing expert opinions and second opinions for complex cases, especially in regions with limited access to specialized healthcare facilities.

Lung Cancer Surgery Market Trends:

• Minimally Invasive Surgery Dominance: The trend toward minimally invasive surgical techniques, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery, was prominent. These techniques were being increasingly adopted due to their benefits, including reduced post-operative pain, quicker recovery, and shorter hospital stays.
• Personalized Treatment Approaches: The integration of molecular profiling and genetic testing into lung cancer treatment decisions was a growing trend. Identifying specific genetic mutations and biomarkers allowed for targeted therapies, impacting surgical choices and overall treatment plans.
• Increased Focus on Early Detection: Early detection of lung cancer was gaining importance as it significantly influences patient outcomes. Greater awareness of risk factors, coupled with advancements in diagnostic imaging technologies, contributed to the trend of detecting lung cancer at earlier stages.
• Collaborative Multidisciplinary Care: Multidisciplinary care teams, comprising medical oncologists, radiation oncologists, pulmonologists, and surgeons, were increasingly working together to create comprehensive treatment plans that incorporate surgery alongside other modalities.

Lung Cancer Surgery Market Restraints:

• Advanced Disease Presentation: Lung cancer is often diagnosed at advanced stages when surgery may not be a viable option due to tumor size, spread, or patient health conditions. This limits the potential pool of patients eligible for surgical intervention.
• High Surgical Risk in Advanced Cases: For patients with advanced-stage lung cancer or underlying health issues, surgical interventions can carry higher risks. Surgeons must carefully evaluate patient suitability for surgery to avoid complications.
• Limited Access to Advanced Healthcare: In certain regions, access to specialized medical facilities and skilled surgical expertise may be limited. This can result in disparities in the availability and quality of lung cancer surgery services.

Recent Developments

New product launches

• In May 2022, Olympus Corporation (Japan) launched the BF-UC190F endobronchial ultrasound (EBUS) bronchoscope. The BF-UC190F is a new generation of EBUS bronchoscope that offers improved image quality and navigation capabilities. It is designed to help surgeons better visualize and biopsy lung cancer lesions.
• In February 2022, Intuitive Surgical Inc. (US) acquired Orpheus Medical (US). Orpheus Medical is a developer of robotically-assisted lung biopsy systems. The acquisition of Orpheus Medical will give Intuitive Surgical a new platform for developing robotically-assisted lung cancer surgery systems.
• In October 2021, KLS Martin Group (Germany) opened a new training center at its site in Jacksonville, Florida, US. The training center is designed to train surgeons on the use of KLS Martin's lung cancer surgery products.

Acquisition and partnerships

• In February 2023, Intuitive Surgical Inc. (US) acquired Auris Health Inc. (US). Auris Health is a developer of robotically-assisted bronchoscopy systems. The acquisition of Auris Health will give Intuitive Surgical a new platform for developing robotically-assisted lung cancer surgery systems.
• In December 2022, Medtronic plc (Ireland) acquired PneumRx Inc. (US). PneumRx is a developer of minimally invasive lung surgery technologies. The acquisition of PneumRx will give Medtronic a new platform for developing minimally invasive lung cancer surgery technologies.
• In October 2022, Olympus Corporation (Japan) acquired TransEnterix Inc. (US). TransEnterix is a developer of robotically-assisted surgery technologies. The acquisition of TransEnterix will give Olympus a new platform for developing robotically-assisted lung cancer surgery technologies.

Figure 2. Global Lung Cancer Surgery Market Share (%), by Surgery Type, 2023

Top companies in Lung Cancer Surgery Market

• Ethicon (Johnson & Johnson)
• Medtronic
• Intuitive Surgical
• Olympus Corporation
• Karl Storz
• Teleflex Incorporated
• Accuray Incorporated
• AngioDynamics
• CONMED Corporation
• Trovagene
• Varian Medical Systems
• Medrobotics Corporation
• Siemens Healthineers
• Atricure, Inc.
• Novadaq Technologies Inc.

*Definition: Lung cancer surgery involves the surgical removal of malignant tumors or affected lung tissue to treat lung cancer. It can encompass various techniques, including open surgery and minimally invasive procedures like video-assisted thoracoscopic surgery (VATS) or robotic-assisted surgery.